
## SUPPLEMENTARY MATERIAL

Supplemental Figure 1. (a) The moon face as well as (b) the skin rash seen on the back (b) at admission to our hospital, and (c) during the 1st week after dupilumab injection.



**Supplementary Figure 2.** The dynamic changes in peripheral blood eosinophil levels during the disease progression of this DRESS patient. wk, week.



J Investig Allergol Clin Immunol 2024; Vol. 34(2) doi: 10.18176/jiaci.0944

**Supplemental Figure 3.** (a) The proportions of inflammatory CD4<sup>+</sup> T cells secreting IL-4, IL-13, IL-5, and IL-31 in peripheral blood at week 0, and (b) the dynamic change with the first four doses of dupilumab injection. HC, health control.

